Albireo Pharma Inc (ALBO) Inventory Turnover Ratio, from third quarter 2022 to third quarter 2021, current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 
Albireo Pharma inc   (NASDAQ: ALBO)
 

Albireo Pharma Inc Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Due to inventory build up in the third quarter 2022, Albireo Pharma Inc 's inventory turnover ratio sequentially decreased to 1.4 in the third quarter 2022, unsurprisingly, as the Albireo Pharma Inc markets continue to deteriorate, and ALBO's faces growing challenges to bring down its inventories. Albireo Pharma Inc 's average inventory processing period in the Sep 30 2022 quarter, has increased to 261 days, from 166 days, in the Jun 30 2022 quarter.

Within Healthcare sector 329 other companies have achieved higher inventory turnover ratio. While in terms of ranking among all other companies, the company has moved form 1656 in the second quarter 2022, to 1723.

ALBO Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Albireo Pharma Inc Market Share?

What is Inventory Turnover Ratio?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ALBO Inventory Turnover Ratio (Sep 30 2022)
III. Quarter		 (Jun 30 2022)
II. Quarter		 (Mar 31 2022)
I. Quarter		 (Dec 31 2021)
IV. Quarter		 (Sep 30 2021)
III. Quarter
Y / Y Inventory Growth 1506.63 % - - - -
Y / Y Cost of Sales Growth 42 % - - - -
Inventory Turnover Ratio (TTM) 1.4 2.2 2.88 13.91 8.8
ALBO's Total Ranking # 1723 # 1656 # 1705 # 0 # 0
Average inventory processing period 260 166 127 26 41
Seq. Inventory Growth 50.24 % 15.1 % 838.66 % -1.02 % -
Seq. Cost of Sales Growth -21.13 % 231.62 % -74.7 % 114.62 % -




Inventory Turnover Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 102
Healthcare Sector # 330
Overall Market # 1723

Inventory Turnover Ratio Statistics
High Average Low
2.2 1.8 1.4
(Jun 30 2022)   (Sep 30 2022)



ALBO Company Profile >> Back to ALBO Efficiency Comparisons >> Compare ALBO Inventory Turnover Ratio to its Competitors

Financial Statements
Albireo Pharma Inc 's Inventories $ 3 Millions Visit ALBO's Balance sheet
Albireo Pharma Inc 's Cost of Revenues TTM $ 3 Millions Visit ALBO's Income Statement
What are ALBO's Sales? Visit ALBO's Sales by Segment

Other Inventory Turnover Ratios
Albireo Pharma Inc 's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Major Pharmaceutical Preparations Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
ALBO's Inventory Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for ALBO's Competitors
Inventory Turnover Ratio for ALBO's Suppliers
Inventory Turnover Ratio for ALBO's Customers

You may also want to know
ALBO's Sales Growth Rates ALBO's Pe Price to earnings ratio ALBO's Receivables Turnover Ratio ALBO's Stock Quote
ALBO's Net Income Growth Rates ALBO's Ps Price to Sales ratio ALBO's Sales per Employee ALBO's Asset Turnover Ratio
ALBO's Net Margin ALBO's Pb Price to Book ratio ALBO's Financial Strength Ratios ALBO's Dividend Payout Ratio



Companies with similar Inventory Turnover Ratio for the quarter ending Sep 30 2022, within Healthcare Sector Inventory Turnover Ratio Cost of revenues at quarter ending Sep 30 2022 Inventories at quarter ending Sep 30 2022
Vystar Corporation  2.21 $ 7.739  Millions$ 4  Millions
Dariohealth Corp   2.20 $ 16.596  Millions$ 8  Millions
Avanos Medical Inc   2.19 $ 366.800  Millions$ 168  Millions
Hologic Inc  2.18 $ 1,227.000  Millions$ 562  Millions
International Stem Cell Corporation  2.17 $ 2.869  Millions$ 1  Millions
Precigen Inc   2.16 $ 14.281  Millions$ 7  Millions
Orchard Therapeutics Plc  2.15 $ 4.338  Millions$ 2  Millions
Medtronic Plc  2.13 $ 10,101.000  Millions$ 4,749  Millions
Abiomed Inc   2.10 $ 200.590  Millions$ 95  Millions
Tvardi Therapeutics Inc   2.10 $ 5.136  Millions$ 2  Millions
Acutus Medical Inc   2.10 $ 33.528  Millions$ 16  Millions
Encision Inc   2.09 $ 3.473  Millions$ 2  Millions
Quotient Limited  2.07 $ 41.155  Millions$ 20  Millions
Lexaria Bioscience Corp   2.05 $ 0.072  Millions$ 0  Millions
Meridian Bioscience Inc   2.04 $ 144.662  Millions$ 71  Millions
Htg Molecular Diagnostics Inc  2.04 $ 3.895  Millions$ 2  Millions
Coherus Oncology inc   2.03 $ 67.985  Millions$ 34  Millions
Surmodics Inc   2.01 $ 20.342  Millions$ 10  Millions
Outset Medical Inc   2.00 $ 95.639  Millions$ 48  Millions
Lifeloc Technologies Inc   1.98 $ 5.030  Millions$ 3  Millions
Neuronetics Inc   1.97 $ 14.725  Millions$ 7  Millions
Procept Biorobotics Corporation  1.97 $ 30.450  Millions$ 15  Millions
Atrion Corporation  1.96 $ 105.838  Millions$ 54  Millions
Biolase Inc   1.96 $ 29.598  Millions$ 15  Millions
Bio rad Laboratories Inc   1.95 $ 1,230.396  Millions$ 630  Millions
Thorne Healthtech Inc   1.95 $ 103.676  Millions$ 53  Millions
Atricure Inc   1.93 $ 79.726  Millions$ 41  Millions
Cardiovascular Systems Inc   1.92 $ 65.830  Millions$ 34  Millions
Pulse Biosciences Inc   1.92 $ 10.526  Millions$ 5  Millions
The Cooper Companies Inc   1.91 $ 1,168.800  Millions$ 611  Millions

Date modified: 2026-08-29T17:15:10+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.